⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 21, 2018Transplantation DirectOpen Access

Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients

Stanley C. Jordan Suphamai Bunnapradist Jonathan S. Bromberg Anthony Langone D. Hiller James Yee John J. Sninsky R. Woodward Arthur J. Matas

View Full Paper

Ask AI

Bookmark

Share

Abstract

The combined use of dd-cfDNA and DSA testing may improve the noninvasive diagnosis of active ABMR in kidney transplant patients. Patients with dd-cfDNA+/ DSA+ results have a high probability of active ABMR.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jordan et al. (2018) studied this question.

synapsesocial.com/papers/69d84d678c03fbaff8beee19 https://doi.org/10.1097/txd.0000000000000821

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial LesionsOriginal Research · 2014 · 1,349 citations
2Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft RecipientsCohort Study · 2017 · 75 citations
3Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney TransplantCohort Study · 2012 · 953 citations
4Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal AllograftsCohort Study · 2013 · 385 citations
5Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific AntibodyCohort Study · 2015 · 356 citations

The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss2016
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation2012
Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information2015
Immune Checkpoint Inhibitor Therapy of Malignancy in Kidney Transplant Recipients: Analysis of Real-world OutcomesTransplantation Direct · 2026
Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 TrialTransplantation Direct · 2026

More from Transplantation Direct

More from University of California, Los Angeles

More from University of Minnesota

More from Vanderbilt University Medical Center